Dana-Farber clinicians and researchers attended the 50th annual meeting of the American Society of Clinical Oncology (ASCO). The meeting was held May 30 – June 4, 2014, in Chicago, Illinois. ASCO is the platform for the release of thousands of scientific abstracts: highly anticipated research news for many people, including patients, caregivers, and the general public. More than 75 Dana-Farber investigators presented new research results at the meeting.
This year's meeting theme of "Science and Society" reflected the coming together of more than 25,000 oncology professionals from a broad range of specialties. Attendees of the annual meeting found leading-edge scientific presentations and comprehensive educational content, including papers and talks from Susan F. Smith Center for Women's Cancers researchers.
Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancerIn the first ovarian cancer study to use a combination of drugs that could be taken orally, Joyce F. Liu, MD, MPH, reports on research that finds significant improvement with the use of a combination drug therapy for recurrent ovarian cancer.
Combination therapy shows promise against forms of breast and ovarian cancer in early clinical trialIn a study conducted by Ursula A. Matulonis, MD, a two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Life-extending ovarian cancer chemotherapy underused, study findsAccording to research by Alexi A. Wright, MD, MPH, patients with non-metastatic ovarian cancer live an average of 16 months longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it.
Palbociclib enters adjuvant testing for stage II-III breast cancerA pilot phase II clinical trial led by Erica Mayer, MD, MPH, is testing the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.
New research shows potential targeted therapy for metastatic, androgen receptor positive, breast cancerResults from an open label clinical study evaluating an oral daily dose of the drug enobosarm conducted by Beth Overmoyer, MD, shows promise for women with metastatic, androgen receptor positive, breast cancer.
See all ASCO news stories
Dana-Farber speakers at the ASCO Annual Meeting 2014
Follow us on Twitter for additional information. Use the hashtag #ASCO14 and follow @ASCO for all conference-related updates.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: